Objective:To analyze the short-term curative effect of roxadustat in the treatment of renal anemia in patients with peritoneal dialysis.Methods:70 patients with peritoneal dialysis renal anemia admitted to the dialysi...Objective:To analyze the short-term curative effect of roxadustat in the treatment of renal anemia in patients with peritoneal dialysis.Methods:70 patients with peritoneal dialysis renal anemia admitted to the dialysis department of our hospital from March 2021-March 2023 were selected as research objects,divided into a research group and a reference group according to random number drawing method,with each group consisting of 35 cases.The patients in the research group were treated with roxadustat,and those in the reference group were treated with recombinant human erythropoietin.The total efficacy,anemia index,iron metabolism index,and occurrence of adverse reactions were compared between the two groups.Results:The total efficacy of the treatment received in the research group was significantly higher than that in the reference group(P<0.05).In terms of anemia indicators,there was no statistically significant difference between the hemoglobin(Hb),the red blood cell(RBC),and the hematocrit(HCT)of both groups(P>0.05)before treatment.After treatment,the anemia indicators of the patients in the research group were significantly better than those in the reference group,(P<0.05).In terms of iron metabolism,before treatment,there was no significant difference between the total iron-binding capacity(TIBC),the transferrin(TRF),the ferritin(FER),and iron(Fe)of both groups(P>0.05).After treatment,the research group’s iron metabolism indicators were significantly better than those of the reference group(P<0.05).The incidence of adverse reactions in the research group was significantly lower than that in the reference group(P<0.05).Conclusion:The short-term curative effect of roxadustat in the treatment of peritoneal dialysis patients was demonstrated through this study,making it a viable treatment option.展开更多
Background: In the near future in Japan, chronic dialysis patients will likely face a situation where the aging and the lengthening of hemodialysis treatment periods will adversely affect the mobility-related activiti...Background: In the near future in Japan, chronic dialysis patients will likely face a situation where the aging and the lengthening of hemodialysis treatment periods will adversely affect the mobility-related activities of daily living (MR-ADL). The aim of this study was to investigate chronological change in MR-ADL among chronic dialysis patients in need of long-term care and the effect of admission to long-term care facilities on their MR-ADL. Methods: Data were analyzed from a long-term care eligibility assessment survey conducted in late March 2009 of 1000 individuals residing in Niigata City, Japan who were approved to receive long-term care. Then data from those individuals who had undergone the assessment survey ≥4 times over a period of ≥4 years were statistically evaluated. To reveal change in MR-ADL, this study performed a three-way analysis of variance with mean survey scores from assessment categories 2 - 5 containing questions related to MR-ADL as the independent variable and the number of eligibility assessment surveys (within-subjects factor), facility admission, and dialysis therapy (between-subjects factors) as dependent variables. Results: We observed the effect of facility admission in individuals aged >70 years for categories 2 - 5, and observed the effect of the number of assessment surveys taken only in women ≥80 years for categories 2 and 5. Regarding the effect of dialysis therapy, female dialysis patients aged ≥80 years and in need of long-term care scored significantly higher on survey items for transferring, grooming, toileting, eating, and instrumental activities of daily living, all of which are indicators of a moderate decline in ADL. Conclusions: Because dialysis is often initiated in women aged around 80 years, ADL in this group of individuals can be improved by the initiation and proper provision of dialysis.展开更多
目的比较每日透析和传统透析在诱导期血液透析中的应用,探讨每日透析用于诱导期血液透析的可行性及优势。方法将兰州大学第二医院肾病中心2013-2014年新进入血液透析治疗的慢性肾衰竭尿毒症患者44例区组随机分配到两个治疗组,其中传统...目的比较每日透析和传统透析在诱导期血液透析中的应用,探讨每日透析用于诱导期血液透析的可行性及优势。方法将兰州大学第二医院肾病中心2013-2014年新进入血液透析治疗的慢性肾衰竭尿毒症患者44例区组随机分配到两个治疗组,其中传统诱导透析组(CHD)22例、每日透析组(DHD)22例。两组患者诱导透析前1 d和第7天时检测尿素氮(BUN)、血肌酐(Scr)、血红蛋白(Hb)、平均动脉压(MAP)、心率(HR)、APACHEⅡ评分,观察治疗期间失衡综合征等并发症及SCL-90量表中的头痛评分、恶心评分、睡眠障碍评分、焦虑评分、躯体化评分、总因子分。结果两组患者入院时BUN、Scr、Hb、MAP、HR、APACHEⅡ评分比较,差异均无统计学意义(P>0.05)。第7天,DHD组患者Scr、MAP、APACHEⅡ评分与CHD组比较,差异有统计学意义[分别为(465.44±117.70)vs(594.60±157.38),(99.71±12.23)vs(109.54±12.14),(13.71±2.13)vs(15.38±1.94),P<0.05]。DHD组头痛评分、恶心评分、睡眠障碍评分、焦虑评分、躯体化评分、总因子分与CHD组比较,差异有统计学意义[1.00 vs 2.00,1.00 vs 2.00,(1.53±0.43)vs(1.92±0.61),(1.28±0.34)vs(1.53±0.37),(1.50±0.46)vs(1.90±0.58),(1.38±0.38)vs(1.68±0.40),P<0.05]。结论在诱导透析期,每日透析代替传统透析能给患者提供一个高效、平稳、安全、舒适的血液净化过程。展开更多
To estimate the size of the novel coronavirus(COVID-19)outbreak in the early stage in Italy,this paper introduces the cumulated and weighted average daily growth rate(WR)to evaluate an epidemic curve.On the basis of a...To estimate the size of the novel coronavirus(COVID-19)outbreak in the early stage in Italy,this paper introduces the cumulated and weighted average daily growth rate(WR)to evaluate an epidemic curve.On the basis of an exponential decay model(EDM),we provide estimations of the WR in four-time intervals from February 27 to April 07,2020.By calibrating the parameters of the EDM to the reported data in Hubei Province of China,we also attempt to forecast the evolution of the outbreak.We compare the EDM applied to WR and the Gompertz model,which is based on exponential decay and is often used to estimate cumulative events.Specifically,we assess the performance of each model to short-term forecast of the epidemic,and to predict the final epidemic size.Based on the official counts for confirmed cases,the model applied to data from February 27 until the 17th of March estimate that the cumulative number of infected in Italy could reach 131,280(with a credibility interval 71,415-263,501)by April 25(credibility interval April 12 to May 3).With the data available until the 24st of March the peak date should be reached on May 3(April 23 to May 23)with 197,179 cumulative infections expected(130,033e315,269);with data available until the 31st of March the peak should be reached on May 4(April 25 to May 18)with 202,210 cumulative infections expected(155.235 e270,737);with data available until the 07st of April the peak should be reached on May 3(April 26 toMay 11)with 191,586(160,861-232,023)cumulative infections expected.Based on the average mean absolute percentage error(MAPE),cumulated infections forecasts provided by the EDM applied to WR performed better across all scenarios than the Gompertz model.An exponential decay model applied to the cumulated and weighted average daily growth rate appears to be useful in estimating the number of cases and peak of the COVID-19 outbreak in Italy and the model was more reliable in the exponential growth phase.展开更多
文摘Objective:To analyze the short-term curative effect of roxadustat in the treatment of renal anemia in patients with peritoneal dialysis.Methods:70 patients with peritoneal dialysis renal anemia admitted to the dialysis department of our hospital from March 2021-March 2023 were selected as research objects,divided into a research group and a reference group according to random number drawing method,with each group consisting of 35 cases.The patients in the research group were treated with roxadustat,and those in the reference group were treated with recombinant human erythropoietin.The total efficacy,anemia index,iron metabolism index,and occurrence of adverse reactions were compared between the two groups.Results:The total efficacy of the treatment received in the research group was significantly higher than that in the reference group(P<0.05).In terms of anemia indicators,there was no statistically significant difference between the hemoglobin(Hb),the red blood cell(RBC),and the hematocrit(HCT)of both groups(P>0.05)before treatment.After treatment,the anemia indicators of the patients in the research group were significantly better than those in the reference group,(P<0.05).In terms of iron metabolism,before treatment,there was no significant difference between the total iron-binding capacity(TIBC),the transferrin(TRF),the ferritin(FER),and iron(Fe)of both groups(P>0.05).After treatment,the research group’s iron metabolism indicators were significantly better than those of the reference group(P<0.05).The incidence of adverse reactions in the research group was significantly lower than that in the reference group(P<0.05).Conclusion:The short-term curative effect of roxadustat in the treatment of peritoneal dialysis patients was demonstrated through this study,making it a viable treatment option.
文摘Background: In the near future in Japan, chronic dialysis patients will likely face a situation where the aging and the lengthening of hemodialysis treatment periods will adversely affect the mobility-related activities of daily living (MR-ADL). The aim of this study was to investigate chronological change in MR-ADL among chronic dialysis patients in need of long-term care and the effect of admission to long-term care facilities on their MR-ADL. Methods: Data were analyzed from a long-term care eligibility assessment survey conducted in late March 2009 of 1000 individuals residing in Niigata City, Japan who were approved to receive long-term care. Then data from those individuals who had undergone the assessment survey ≥4 times over a period of ≥4 years were statistically evaluated. To reveal change in MR-ADL, this study performed a three-way analysis of variance with mean survey scores from assessment categories 2 - 5 containing questions related to MR-ADL as the independent variable and the number of eligibility assessment surveys (within-subjects factor), facility admission, and dialysis therapy (between-subjects factors) as dependent variables. Results: We observed the effect of facility admission in individuals aged >70 years for categories 2 - 5, and observed the effect of the number of assessment surveys taken only in women ≥80 years for categories 2 and 5. Regarding the effect of dialysis therapy, female dialysis patients aged ≥80 years and in need of long-term care scored significantly higher on survey items for transferring, grooming, toileting, eating, and instrumental activities of daily living, all of which are indicators of a moderate decline in ADL. Conclusions: Because dialysis is often initiated in women aged around 80 years, ADL in this group of individuals can be improved by the initiation and proper provision of dialysis.
文摘目的比较每日透析和传统透析在诱导期血液透析中的应用,探讨每日透析用于诱导期血液透析的可行性及优势。方法将兰州大学第二医院肾病中心2013-2014年新进入血液透析治疗的慢性肾衰竭尿毒症患者44例区组随机分配到两个治疗组,其中传统诱导透析组(CHD)22例、每日透析组(DHD)22例。两组患者诱导透析前1 d和第7天时检测尿素氮(BUN)、血肌酐(Scr)、血红蛋白(Hb)、平均动脉压(MAP)、心率(HR)、APACHEⅡ评分,观察治疗期间失衡综合征等并发症及SCL-90量表中的头痛评分、恶心评分、睡眠障碍评分、焦虑评分、躯体化评分、总因子分。结果两组患者入院时BUN、Scr、Hb、MAP、HR、APACHEⅡ评分比较,差异均无统计学意义(P>0.05)。第7天,DHD组患者Scr、MAP、APACHEⅡ评分与CHD组比较,差异有统计学意义[分别为(465.44±117.70)vs(594.60±157.38),(99.71±12.23)vs(109.54±12.14),(13.71±2.13)vs(15.38±1.94),P<0.05]。DHD组头痛评分、恶心评分、睡眠障碍评分、焦虑评分、躯体化评分、总因子分与CHD组比较,差异有统计学意义[1.00 vs 2.00,1.00 vs 2.00,(1.53±0.43)vs(1.92±0.61),(1.28±0.34)vs(1.53±0.37),(1.50±0.46)vs(1.90±0.58),(1.38±0.38)vs(1.68±0.40),P<0.05]。结论在诱导透析期,每日透析代替传统透析能给患者提供一个高效、平稳、安全、舒适的血液净化过程。
文摘To estimate the size of the novel coronavirus(COVID-19)outbreak in the early stage in Italy,this paper introduces the cumulated and weighted average daily growth rate(WR)to evaluate an epidemic curve.On the basis of an exponential decay model(EDM),we provide estimations of the WR in four-time intervals from February 27 to April 07,2020.By calibrating the parameters of the EDM to the reported data in Hubei Province of China,we also attempt to forecast the evolution of the outbreak.We compare the EDM applied to WR and the Gompertz model,which is based on exponential decay and is often used to estimate cumulative events.Specifically,we assess the performance of each model to short-term forecast of the epidemic,and to predict the final epidemic size.Based on the official counts for confirmed cases,the model applied to data from February 27 until the 17th of March estimate that the cumulative number of infected in Italy could reach 131,280(with a credibility interval 71,415-263,501)by April 25(credibility interval April 12 to May 3).With the data available until the 24st of March the peak date should be reached on May 3(April 23 to May 23)with 197,179 cumulative infections expected(130,033e315,269);with data available until the 31st of March the peak should be reached on May 4(April 25 to May 18)with 202,210 cumulative infections expected(155.235 e270,737);with data available until the 07st of April the peak should be reached on May 3(April 26 toMay 11)with 191,586(160,861-232,023)cumulative infections expected.Based on the average mean absolute percentage error(MAPE),cumulated infections forecasts provided by the EDM applied to WR performed better across all scenarios than the Gompertz model.An exponential decay model applied to the cumulated and weighted average daily growth rate appears to be useful in estimating the number of cases and peak of the COVID-19 outbreak in Italy and the model was more reliable in the exponential growth phase.
